Announcement

Collapse
No announcement yet.

Abstract: Diquafosol

Collapse
X
  • Filter
  • Time
  • Show
Clear All
new posts

  • Abstract: Diquafosol

    Efficacy and Safety of Diquafosol Ophthalmic Solution in Patients with Dry Eye Syndrome: A Japanese Phase 2 Clinical Trial.

    OBJECTIVE:
    To investigate the dose-dependent efficacy and safety of diquafosol ophthalmic solution for the treatment of dry eye syndrome.
    DESIGN:
    Randomized, double-masked, multicenter, parallel-group, placebo-controlled trial.
    PARTICIPANTS:
    A total of 286 Japanese patients with dry eye who were prescribed topical diquafosol (1%, n = 96; 3%, n = 96) or placebo ophthalmic solution (n = 94).
    METHODS:
    After a washout period of 2 weeks, qualified subjects were randomized to receive a single drop of 1% or 3% diquafosol or placebo ophthalmic solutions 6 times per day for 6 weeks.
    MAIN OUTCOME MEASURES:
    The primary outcome measure was fluorescein corneal staining score assessment. The secondary outcome measures were Rose Bengal corneal and conjunctival staining scores, tear break-up time (BUT), and subjective symptom assessment. Safety measures were clinical blood and urine examination and recording of adverse events.
    RESULTS:
    Fluorescein corneal staining scores significantly improved with both 1% and 3% topical diquafosol compared with placebo at 4 weeks, respectively (P = 0.037, P = 0.002). There was a dose-dependent effect among the groups. Rose Bengal corneal and conjunctival staining scores also improved significantly with both 1% and 3% diquafosol compared with placebo (P = 0.007 and P = 0.004, respectively). Subjective dry eye symptom scores significantly improved with both diquafosol ophthalmic solutions (P ≤ 0.033), although there were no significant differences in BUT compared with placebo. No significant differences between the treatment groups were observed in relation to the occurrence of adverse events.
    CONCLUSIONS:
    Both 1% and 3% diquafosol ophthalmic solutions are considered effective and safe for the treatment of dry eye syndrome.
    FINANCIAL DISCLOSURE(S):
    Proprietary or commercial disclosure may be found after the references.
    Ophthalmology. 2012 Jun 25. [Epub ahead of print]
    Matsumoto Y, Ohashi Y, Watanabe H, Tsubota K; Diquafosol Ophthalmic Solution Phase 2 Study Group*.
    Source
    Department of Ophthalmology, Keio University School of Medicine, Tokyo, Japan.
    Rebecca Petris
    The Dry Eye Zone
Previously entered content was automatically saved. Restore or Discard.
Auto-Saved
Smile :) Biggrin :D Wink ;) Rolleyes :rolleyes: Tongue :p Cool :cool: Redface :o Confused :confused: Eek :eek: Frown :( Mad :mad:
x
Insert: Thumbnail Small Medium Large Fullsize Remove  
x
Working...
X